Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study.
Blauvelt A, Pariser DM, Tyring S, Bagel J, Alexis AF, Soung J, Armstrong AW, Muscianisi E, Kianifard F, Steadman J, Sarkar RP, Garcet S, Krueger JG.
Blauvelt A, et al. Among authors: bagel j.
J Dermatol Sci. 2023 Jan;109(1):12-21. doi: 10.1016/j.jdermsci.2023.01.003. Epub 2023 Jan 9.
J Dermatol Sci. 2023.
PMID: 36690571
Free article.
Clinical Trial.